184 related articles for article (PubMed ID: 15698538)
1. Major impact of hormonal therapy in localized prostate cancer--death can already be an exception.
Labrie F; Cusan L; Gomez J; Luu-The V; Candas B; Bélanger A; Labrie C
J Steroid Biochem Mol Biol; 2004 Dec; 92(5):327-44. PubMed ID: 15698538
[TBL] [Abstract][Full Text] [Related]
2. [New approach in the treatment of prostatic cancer: combined use of a LHRH agonist and an androgen antagonist].
Labrie F; Dupont A; Belanger A; Lefebvre FA; Raynaud JP
J Pharmacol; 1983; 14 Suppl 3():117-35. PubMed ID: 6423907
[TBL] [Abstract][Full Text] [Related]
3. Hormonal therapy of prostate cancer.
Labrie F
Prog Brain Res; 2010; 182():321-41. PubMed ID: 20541672
[TBL] [Abstract][Full Text] [Related]
4. [Keyrole of endocrinology in the victory against prostate cancer].
Labrie F
Bull Cancer; 2006 Sep; 93(9):949-58. PubMed ID: 16980238
[TBL] [Abstract][Full Text] [Related]
5. Combination therapy with flutamide and castration (orchiectomy or LHRH agonist): the minimal endocrine therapy in both untreated and previously treated patients with advanced prostate cancer.
Labrie F; Dupont A; Giguère M; Borsanyi JP; Lacourciere Y; Bélanger A; Lachance R; Emond J; Monfette G
Prog Clin Biol Res; 1988; 260():41-62. PubMed ID: 3283766
[TBL] [Abstract][Full Text] [Related]
6. Is dehydroepiandrosterone a hormone?
Labrie F; Luu-The V; Bélanger A; Lin SX; Simard J; Pelletier G; Labrie C
J Endocrinol; 2005 Nov; 187(2):169-96. PubMed ID: 16293766
[TBL] [Abstract][Full Text] [Related]
7. Luteinizing hormone-releasing hormone agonists in the treatment of prostate cancer: a review of their discovery, development, and place in therapy.
Moreau JP; Delavault P; Blumberg J
Clin Ther; 2006 Oct; 28(10):1485-508. PubMed ID: 17157109
[TBL] [Abstract][Full Text] [Related]
8. Gonadotropin-releasing hormone agonists in the treatment of prostate cancer.
Labrie F; Bélanger A; Luu-The V; Labrie C; Simard J; Cusan L; Gomez J; Candas B
Endocr Rev; 2005 May; 26(3):361-79. PubMed ID: 15867098
[TBL] [Abstract][Full Text] [Related]
9. [From the gene to the clinic: prostate cancer death can now be an exception?].
Labrie F; Cusan L; Gomez JL; Candas B; Bélanger A; Luu-The V; Labrie C; Simard J
Med Sci (Paris); 2003 Oct; 19(10):910-9. PubMed ID: 14612999
[TBL] [Abstract][Full Text] [Related]
10. Endocrine therapy: where do we stand and where are we going?
Schröder FH
Cancer Surv; 1991; 11():177-94. PubMed ID: 1841751
[TBL] [Abstract][Full Text] [Related]
11. Long-term effectiveness of luteinizing hormone-releasing hormone agonist or antiandrogen monotherapy in elderly men with localized prostate cancer (T1-2): a retrospective study.
Raina R; Pahalajani G; Agarwal A; Zippe C
Asian J Androl; 2007 Mar; 9(2):253-8. PubMed ID: 17334592
[TBL] [Abstract][Full Text] [Related]
12. Science behind total androgen blockade: from gene to combination therapy.
Labrie F; Bélanger A; Dupont A; Luu-The V; Simard J; Labrie C
Clin Invest Med; 1993 Dec; 16(6):475-92. PubMed ID: 8013153
[TBL] [Abstract][Full Text] [Related]
13. New hormonal therapy in prostatic carcinoma: combined treatment with an LHRH agonist and an antiandrogen.
Labrie F; Dupont A; Belanger A; Cusan L; Lacourciere Y; Monfette G; Laberge JG; Emond JP; Fazekas AT; Raynaud JP; Husson JM
Clin Invest Med; 1982; 5(4):267-75. PubMed ID: 6819101
[TBL] [Abstract][Full Text] [Related]
14. Current status and prospects of androgen depletion therapy for prostate cancer.
Akaza H
Best Pract Res Clin Endocrinol Metab; 2008 Apr; 22(2):293-302. PubMed ID: 18471787
[TBL] [Abstract][Full Text] [Related]
15. Alternative nonsteroidal antiandrogen therapy for advanced prostate cancer that relapsed after initial maximum androgen blockade.
Suzuki H; Okihara K; Miyake H; Fujisawa M; Miyoshi S; Matsumoto T; Fujii M; Takihana Y; Usui T; Matsuda T; Ozono S; Kumon H; Ichikawa T; Miki T;
J Urol; 2008 Sep; 180(3):921-7. PubMed ID: 18635218
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of primary hormonal therapy for patients with localized and locally advanced prostate cancer: a retrospective multicenter study.
Ueno S; Namiki M; Fukagai T; Ehara H; Usami M; Akaza H
Int J Urol; 2006 Dec; 13(12):1494-500. PubMed ID: 17118024
[TBL] [Abstract][Full Text] [Related]
17. Androgen-deprivation therapy as primary treatment for localized prostate cancer: data from Cancer of the Prostate Strategic Urologic Research Endeavor (CaPSURE).
Kawakami J; Cowan JE; Elkin EP; Latini DM; DuChane J; Carroll PR;
Cancer; 2006 Apr; 106(8):1708-14. PubMed ID: 16544313
[TBL] [Abstract][Full Text] [Related]
18. Tolerability, efficacy and pharmacokinetics of bicalutamide 300 mg, 450 mg or 600 mg as monotherapy for patients with locally advanced or metastatic prostate cancer, compared with castration.
Tyrrell CJ; Iversen P; Tammela T; Anderson J; Björk T; Kaisary AV; Morris T
BJU Int; 2006 Sep; 98(3):563-72. PubMed ID: 16771791
[TBL] [Abstract][Full Text] [Related]
19. Maximal androgen blockade for advanced prostate cancer.
Klotz L
Best Pract Res Clin Endocrinol Metab; 2008 Apr; 22(2):331-40. PubMed ID: 18471790
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of primary hormone therapy for localized or locally advanced prostate cancer: results of a 10-year follow-up.
Akaza H; Homma Y; Usami M; Hirao Y; Tsushima T; Okada K; Yokoyama M; Ohashi Y; Aso Y;
BJU Int; 2006 Sep; 98(3):573-9. PubMed ID: 16925756
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
